Efficacy and Patient-Reported Outcomes of a New Mometasone Cream Treating Atopic Eczema

Ruzicka, Thomas; Willers, Christoph; Wigger‐Alberti, W.

doi:10.1159/000341809

Cited by 12 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In further studies it was shown that a regimen of mometasone furoate 0.1% cream applied 2 or 3 days/week for up to 36 weeks, and 2 days/week for 26 weeks was prophylactic in both adults with eczema35 and children with atopic dermatitis 36. Recently, new cream formulations of mometasone furoate have become available, which have been shown to be bioequivalent to the older preparations 7, 37, 38, 39…”

Section: Clinical Efficacymentioning

confidence: 99%

Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids

Spada¹,

Barnes²,

Greive³

2018

Aust J Dermatology

View full text Add to dashboard Cite

Derivatives of hydrocortisone, such as mometasone furoate, a (2′) furoate‐17 ester with chlorine substitutions at positions 9 and 21, have been designed to improve efficacy and reduce the incidence of adverse effects. An extensive literature search of MEDLINE, Embase and other databases was conducted to review the safety and efficacy of various formulations of topical mometasone furoate. Mometasone furoate exhibits high potency with greater anti‐inflammatory activity and a longer duration of action than betamethasone. In clinical trials, mometasone furoate shows comparable or significantly better efficacy, depending on the comparator, in all indications studied in both adults and children. It is well tolerated with only transient, mild to moderate local adverse effects. It is characterised by low systemic availability due to its high lipophilicity, low percutaneous absorption and rapid hepatic biotransformation, and consequently has no significant effect on the hypothalamic‐pituitary‐adrenal axis. The molecular biotransformation of mometasone furoate in the skin results in a lower affinity with dermal cells than epidermal cells, which contributes to its low atrophogenicity. Sensitisation to mometasone furoate is low. Overall, mometasone furoate is a highly efficacious potent corticosteroid with a low risk of both local and systemic adverse effects.

show abstract

Section: Clinical Efficacymentioning

confidence: 99%

Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids

Spada¹,

Barnes²,

Greive³

2018

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

“…A total of 12 trials [112][113][114][115][116][117][118][119][120][121][122] were reported from 2000 onwards, with two trials reported together in one report. 113 Ten of these trials compared novel topical corticosteroids with standard topical corticosteroids and one trial 118 compared a topical corticosteroid with and without the addition of a penetration-enhancing drug.…”

Section: Studiesmentioning

confidence: 99%

“…This trial report was very short and there were very few details provided about the trial. Nine of these trials [112][113][114][115][116][117]122 compared treatments exclusively in children and three trials [118][119][120] did not report the age of the participants. Six of the trials 113,[116][117][118]121 had > 100 participants and six 112,114,115,119,120,122 had ≤ 50 participants.…”

Section: Studiesmentioning

confidence: 99%

“…Nine of these trials [112][113][114][115][116][117]122 compared treatments exclusively in children and three trials [118][119][120] did not report the age of the participants. Six of the trials 113,[116][117][118]121 had > 100 participants and six 112,114,115,119,120,122 had ≤ 50 participants. The treatment regimens varied, with one trial providing 7 days of treatment as required over an 18-week period 116 one trial providing either twice daily treatment for 8 weeks or twice daily treatment for four consecutive days per week for 8 weeks, 122 and the other trials providing continuous treatment for periods from 2 weeks to 42 days.…”

Section: Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Scoping systematic review of treatments for eczema

Nankervis

Kim

Delamere

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

BackgroundEczema is a very common chronic inflammatory skin condition.ObjectivesTo update the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) systematic review of treatments for atopic eczema, published in 2000, and to inform health-care professionals, commissioners and patients about key treatment developments and research gaps.Data sourcesElectronic databases including MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Skin Group Specialised Register, Latin American and Caribbean Health Sciences Literature (LILACS), Allied and Complementary Medicine Database (AMED) and Cumulative Index to Nursing and Allied Health Literature (CINAHL) were searched from the end of 2000 to 31 August 2013. Retrieved articles were used to identify further randomised controlled trials (RCTs).Review methodsStudies were filtered according to inclusion criteria and agreed by consensus in cases of uncertainty. Abstracts were excluded and non-English-language papers were screened by international colleagues and data were extracted. Only RCTs of treatments for eczema were included, as other forms of evidence are associated with higher risks of bias. Inclusion criteria for studies included availability of data relevant to the therapeutic management of eczema; mention of randomisation; comparison of two or more treatments; and prospective data collection. Participants of all ages were included. Eczema diagnosis was determined by a clinician or according to published diagnostic criteria. The risk of bias was assessed using the Cochrane Collaboration risk-of-bias tool. We used a standardised approach to summarising the data and the assessment of risk of bias and we made a clear distinction between what the studies found and our own interpretation of study findings.ResultsOf 7198 references screened, 287 new trials were identified spanning 92 treatments. Trial reporting was generally poor (randomisation method: 2% high, 36% low, 62% unclear risk of bias; allocation concealment: 3% high, 15% low, 82% unclear risk of bias; blinding of the intervention: 15% high, 28% low, 57% unclear risk of bias). Only 22 (8%) trials were considered to be at low risk of bias for all three criteria. There was reasonable evidence of benefit for the topical medications tacrolimus, pimecrolimus and various corticosteroids (with tacrolimus superior to pimecrolimus and corticosteroids) for both treatment and flare prevention; oral ciclosporin; oral azathioprine; narrow band ultraviolet B (UVB) light; Atopiclair™ and education. There was reasonable evidence to suggest no clinically useful benefit for twice-daily compared with once-daily topical corticosteroids; corticosteroids containing antibiotics for non-infected eczema; probiotics; evening primrose and borage oil; ion-exchange water softeners; protease inhibitor SRD441 (Serentis Ltd); furfuryl palmitate in emollient; cipamfylline cream; andMycobacterium vaccaevaccine. Additional research evidence is needed for emollients, bath additives, antibacterials, specialist clothing and complementary and alternative therapies. There was no RCT evidence for topical corticosteroid dilution, impregnated bandages, soap avoidance, bathing frequency or allergy testing.LimitationsThe large scope of the review coupled with the heterogeneity of outcomes precluded formal meta-analyses. Our conclusions are still limited by a profusion of small, poorly reported studies.ConclusionsAlthough the evidence base of RCTs has increased considerably since the last NIHR HTA systematic review, the field is still severely hampered by poor design and reporting problems including failure to register trials and declare primary outcomes, small sample size, short follow-up duration and poor reporting of risk of bias. Key areas for further research identified by the review include the optimum use of emollients, bathing frequency, wash products, allergy testing and antiseptic treatments. Perhaps the greatest benefit identified is the use of twice weekly anti-inflammatory treatment to maintain disease remission. More studies need to be conducted in a primary care setting where most people with eczema are seen in the UK. Future studies need to use the same core set of outcomes that capture patient symptoms, clinical signs, quality of life and the chronic nature of the disease.FundingThe National Institute for Health Research Programme Grants for Applied Research programme.

show abstract

“…Already available, a new MF light cream with 33% of water content on the base of an oil in water (O/W) formulation has been created to overwhelm classical MF formulations [32]. Studies have assessed similar bioavailability, efficacy and tolerability compared to the previous MF cream although with the enhanced cosmetic properties of a lighter cream [32,33]. Concurrently, an innovative MF non-alcoholic emulsion with 36% water content has been developed to provide emollient properties and avoid the risk of skin irritation and dryness derived from the use of alcohol-containing solutions.…”

Section: New Pharmaceutical Formulations Of Topical Corticosteroidsmentioning

confidence: 99%

Topical Corticosteroids in Dermatology: From Chemical Development to Galenic Innovation and Therapeutic Trends

Gual¹,

Pau-Charles²,

Abeck³

2015

J Clin Exp Dermatol Res

View full text Add to dashboard Cite

Topical corticosteroids are the cornerstone therapy for many inflammatory skin conditions. In recent decades, the development of new molecules with improved benefit/risk ratio and innovative galenic formulations has boosted the field of topical corticosteroid therapy. Alternative classifications of topical corticosteroids have been introduced taking into consideration the potential adverse effects of each molecule in order to provide useful information for clinical practice. Concurrently, new therapeutic regimens with topical corticosteroids have been proposed to provide longterm approaches for the management of chronic relapsing inflammatory skin diseases.The aim of this review is to provide an overview of topical corticosteroids focusing on the recent research performed in the fields of classification methods, galenic formulations and therapeutic strategies.

show abstract

Efficacy and Patient-Reported Outcomes of a New Mometasone Cream Treating Atopic Eczema

Cited by 12 publications

References 20 publications

Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids

Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids

Scoping systematic review of treatments for eczema

Topical Corticosteroids in Dermatology: From Chemical Development to Galenic Innovation and Therapeutic Trends

Contact Info

Product

Resources

About